Biotech discovery is immune to the market especially when it’s a game changing drug, first in class and has no competitors in this space for secondary brain injury and cardiovascular protection in all strokes at a 18 million market cap. Will become a 100 million dollar plus company just like other drugs in the primary brain injury space but NYR has greater potential and market opportunities
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)